ZEISS PALM MicroBeam IV module Rel 4.2

ZEISS PALM MicroBeam IV 模块 Rel 4.2

• 批准号: 8052425
• 负责人: Sashwati Roy
• 金额: $ 29.69万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-15 至 2012-10-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052425
• 关键词: Academic Medical Centers; Admixture; Affect; Applications Grants; Area; Award; Biology; Cells; Child; Clinical Sciences; Clinical and Translational Science Awards; Commit; Communities; Core Facility; DNA; Development; Diagnostics Research; Direct Costs; Dissection; Equipment; Extramural Activities; Faculty; Funding; Future; Gene Expression; Germany; Goals; Heterogeneity; Housing; Institution; Lasers; Legal patent; Methodology; Methods; Microdissection; Minor; Molecular; Molecular Profiling; National Center for Research Resources; Ohio; Outcome; Pathology; Population; Productivity; Proteins; Proteomics; RNA; Request for Proposals; Research; Research Personnel; Research Project Grants; Resources; Sampling; Technology; Tissues; Translational Research; United States National Institutes of Health; Universities; indexing; instrument; instrumentation; novel; pressure; programs; response

DESCRIPTION (provided by applicant): This proposal requests NCRR support for the acquisition of state-of-the-art PALM MicroBEAM IV laser capture micro-dissection instrument (PALM MicroBeam) from Zeiss (P.A.L.M. Microlaser Technologies, Carl Zeiss Group, Bernried, Germany). This equipment would be the first laser capture equipment for shared use in the Ohio State University (OSU). The entire OSU or nearby Nationwide Children's do not have a Laser Capture Micro-dissection (LCM) core facility. The requested instrument will be housed in Laser Capture Molecular Core facilities (https://lcm.osu.edu/index.cfm) in the Ohio State University Medical Center (OSUMC). ). Space and relevant resources have been committed for the proposed core in response to faculty requests. In May, 2008 OSU was awarded the prestigious NIH Clinical and Translational Science Award (CTSA). LCM novel methodology development was a priority area in this award. The PI together with two other investigators was awarded research grant to develop proteomics and miR profiling methods from LCM samples. These methods are now ready for dissemination; OSU CTSA has announced matching funds for dissemination of methodology developed via Laser Capture Molecular Core to OSU investigators. The requested PALM MicroBeam has the patented laser microdissection and pressure catapulting (LMPC) technology. The molecular examination of pathologically altered cells and tissues at the DNA, RNA, and protein level has revolutionized research and diagnostics in pathology. However, the inherent heterogeneity of primary tissues with an admixture of various reactive cell populations can affect the outcome and interpretation of molecular studies. Particularly suited to study spatially resolved biology, LMPC enables the investigator to isolate samples of pure cell populations as small as single cells or even sub cellular fragments for further molecular profiling (gene expression, proteomics). The equipment is expected to directly enhance the productivity of a minimum of 14 (8 major users and 6 minor users) currently funded federal research grants totaling > $ 2.5 million in annual direct costs. The long term goals of the core facility are to provide diverse research community of OSUMC and affiliated research institutions with the latest LCM technology and applications. The funding of this instrumentation grant application for LCM will transform the capability of the federally funded research programs at the OSU, increasing their productivity and competitiveness for future extramural funding that can impact NIH and/or other extra mural funded research at OSU. PUBLIC HEALTH RELEVANCE: PALM MicroBeam IV is high-throughput laser microdissection (LCM) equipment. Using this technology, individual cells and specific regions can be captured from clinically relevant small tissue section for genomic and proteomic analyses. The technology is best suited and is essential for human health relevant translational research.

描述（由申请人提供）：该提案请求NCRR支持从Zeiss获得最先进的棕榈微光iv激光捕获捕获微脱轴仪（Palm Microbeam）（P.A.L.L.M. Microlaser Technologies，Carl Zeiss Group，bernried，德国，Carl Zeiss Group，Carl Zeiss Group）。该设备将是俄亥俄州立大学（OSU）共享使用的第一个激光捕获设备。整个OSU或附近的全国儿童都没有激光捕获微型拆卸（LCM）核心设施。所请求的仪器将安置在俄亥俄州立大学医学中心（OSUMC）的激光捕获分子核心设施（https://lcm.osu.edu/index.cfm）中。 ）。为了响应教师的要求，已为拟议的核心提供了空间和相关资源。 2008年5月，OSU被授予著名的NIH临床和转化科学奖（CTSA）。 LCM新方法开发是该奖项的优先领域。 PI与另外两名研究人员一起获得了研究赠款，以开发LCM样品的蛋白质组学和MIR分析方法。这些方法现在已经准备好传播了。 OSU CTSA宣布了通过激光捕获分子核与OSU研究人员开发的方法的匹配资金。请求的棕榈微束具有专利的激光微解剖和压力弹射（LMPC）技术。 DNA，RNA和蛋白质水平的病理改变细胞和组织的分子检查彻底改变了病理学的研究和诊断。但是，与各种反应性细胞群体混合的原代组织的固有异质性会影响分子研究的结果和解释。 LMPC特别适合研究空间分辨的生物学，使研究者能够分离出像单个细胞一样小的纯细胞群体，甚至可以将亚细胞片段分离出来，以进一步分子分析（基因表达，蛋白质组学）。预计该设备将直接提高至少14个（8个主要用户和6个未成年人）的生产率，目前为联邦研究提供了总计250万美元的直接成本。核心设施的长期目标是为OSUMC和附属研究机构提供最新的LCM技术和应用程序。该仪器拨款申请的资金将改变OSU中联邦资助的研究计划的能力，从而提高了其生产力和竞争力对未来的壁外资金，这可能会影响NIH和/或OSU的其他额外壁画研究。 公共卫生相关性：Palm Microbeam IV是高通量激光显微解剖（LCM）设备。使用该技术，可以从临床相关的小组织部分中捕获单个细胞和特定区域，以进行基因组和蛋白质组学分析。该技术最适合，对于人类健康相关的转化研究至关重要。